WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/...to-highlight medbox">HIV/2017.03
more
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PLOS ONE | https://doi.org/10.1371/journal.pone.0192765 February 23, 2018
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Policy
July 2012
Working Paper No. 3
Joint Action for Results
UNAIDS Outcome Framework: Business Case 2009–2011
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
· Relevant interventions
· HIV country profiles
· Adolescents country profiles
International Journal of Infectious Diseases 80 (2019) 10–15
journal homepage: www.elsevier.com/locate/ijid
World Health Organization Department of Reproductive Health and Research
Brocher Foundation, Hermance, Geneva, Switzerland, 27–29 April 2016
“Continuum of HIV services refers to a comprehensive package of HIV prevention, diagnostic, treatment, care and support services provided for people at risk of ...medbox">HIV infection or living with HIV and their families”
August, 2018
more
Accelerating HIV prevention to reduce new infections by 75%
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of ...ght medbox">HIV-positive adults. They should be read in conjunction with other published BHIVA guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more